This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Anomalous Portal Venous Connection문맥결합이상

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q26.5 (Anomalous portal venous connection) | Special Copayment Reduction: V150
B. Synonyms—
C. Adult onsetLikelihood of first presentation in adulthood: moderate — varies according to the type and severity of the anomalous portal venous connection. In congenital portosystemic shunt (CPSS), mild cases may remain asymptomatic until adulthood and be diagnosed for the first time with hepatic encephalopathy, pulmonary arterial hypertension, hepatopulmonary syndrome, nodular hyperplasia of the liver, etc. Severe shunts present in the neonatal period or childhood with hyperammonemia and other findings.
1. HistoryHistory of the description of congenital portal venous anomalies; first reported by Abernethy in 1793; development of modern classification systems.
2. CausesAbnormal development of the portal venous system in fetal life; non-closure of the ductus venosus; abnormal portal–systemic venous connection.
3. GeneticsMostly sporadic; studies on NOTCH signaling and vascular development genes; a genetic association is possible when accompanied by congenital heart malformations.
4. General epidemiologyPrevalence of congenital portosystemic shunt about 1/30,000–50,000; female predominance (2:1); associated malformations are frequent.
5. PathophysiologyReduced/bypassed portal blood flow → impaired liver development, systemic exposure to toxins such as ammonia → hepatic encephalopathy, pulmonary and renal complications.
6. SymptomsHyperammonemia, hepatic encephalopathy, developmental delay (children), pulmonary arterial hypertension, hepatopulmonary syndrome, liver nodules, nephrolithiasis.
7. SignsHepatomegaly or liver atrophy, signs of encephalopathy, cyanosis (hepatopulmonary syndrome), signs of pulmonary arterial hypertension.
8. ScreeningNeonatal hyperammonemia screening; abdominal ultrasound and Doppler; CT/MR angiography.
9. DiagnosisAbdominal Doppler ultrasound, CT/MR angiography, nuclear medicine liver function tests, serum ammonia and bile acids, liver biopsy.
10. TreatmentShunt closure (surgery or percutaneous embolization); liver transplantation (for severe liver damage); conservative management (low-protein diet, lactulose, rifaximin).
11. PrognosisGood prognosis with early shunt closure; untreated, risk of progression of hepatic encephalopathy and pulmonary arterial hypertension; complications need monitoring after liver transplantation.
12. PreventionPrimary prevention is difficult; early detection through neonatal screening; prevention of complications by shunt closure.
13. ReferencesAbernethy J, 1793; Morgan G et al., J Pediatr Gastroenterol Nutr 2015, and 8 other references

1. History

Anomalous Portal Venous Connection (ICD-10 Q26.5) includes congenital vascular malformations in which the portal vein does not drain normally into the liver but is abnormally connected to the systemic venous system (inferior vena cava, renal vein, iliac vein, atrium, etc.), or in which the portal vein fails to form congenitally. The most important entity in this group is Congenital Portosystemic Shunt (CPSS), also called the Abernethy malformation.

The earliest description was made in 1793 by the English surgeon John Abernethy. At the autopsy of a 10-day-old girl who had died, Abernethy found an anomaly in which the portal vein did not drain into the liver at all and the inferior mesenteric vein connected directly to the inferior vena cava, and he reported that the liver was markedly small and the gallbladder was absent. This type 1 anomaly (no intrahepatic portal flow) was later named the 'Abernethy malformation'.

Sporadic autopsy reports followed over the subsequent decades, but the condition gained clinical attention only after advances in imaging technology in the late 20th century. In 1994, Morgan and Superina proposed a systematic classification of the Abernethy malformation. Type 1 is the absence of intrahepatic portal flow and is subdivided into type 1a (mesenteric–inferior vena cava shunt) and type 1b (splenic vein–inferior vena cava shunt). Type 2 is the presence of a side-to-side shunt with partially preserved intrahepatic portal veins. This classification system is still widely used today.

In addition, congenital absence of the portal vein, patent ductus venosus, portal vein thrombosis, and congenital extrahepatic portosystemic shunts are included in the category of Q26.5. The ductus venosus is a structure that, in fetal life, connects the portal vein and the inferior vena cava to send placental blood to the heart, bypassing the liver; it closes within a few weeks after birth to become the ligamentum venosum. If this closure does not occur, patent ductus venosus develops and the portosystemic shunt persists. In the modern era, these vascular anomalies can be diagnosed during life by abdominal ultrasound, CT, and MRI, and various treatment options have been developed, including percutaneous vascular embolization, surgical ligation, and liver transplantation.

In Korea as well, cases of congenital portosystemic shunt have been reported in the field of pediatric gastroenterology, and guidelines for the diagnosis and treatment of cases presenting with complications such as hyperammonemia, hepatic encephalopathy, and pulmonary arterial hypertension are gradually being established. Through Special Copayment Reduction V150 registration, support as a rare disease is available.

2. Causes

Anomalous portal venous connection arises from abnormalities in the development of the portal venous system in fetal life. Normally, the portal vein is formed between weeks 5 and 10 of gestation through a complex process of vascular remodeling derived from the vitelline veins. In this process, specific portions of the vitelline veins selectively persist or regress, ultimately completing the normal anatomy of the portal vein, splenic vein, superior mesenteric vein, and inferior mesenteric vein.

When this process proceeds abnormally, various types of portal anomalies arise. The most representative, congenital portosystemic shunt (Abernethy malformation), occurs when an abnormal connection between the mesenteric–portal system and the systemic venous system forms in fetal life, or when the fetal portal–systemic venous connection (ductus venosus) fails to close after birth (patent ductus venosus). In type 1 Abernethy malformation, the portal vein itself does not form, and mesenteric blood drains directly into the systemic veins (inferior vena cava or renal vein, etc.). In type 2, the portal vein is partially present, but a side-to-side shunt is formed.

Patent ductus venosus results from failure of the normal postnatal closure of the ductus venosus, so that a substantial portion of portal blood bypasses the liver and flows directly into the inferior vena cava. The shunt volume varies according to the diameter of the ductus venosus. Cavernous transformation of the portal vein develops from collateral vessel formation following portal vein thrombosis, and both congenital and acquired forms exist.

Anomalous portal venous connection is often accompanied by other congenital malformations. In particular, accompanying congenital heart disease (atrial septal defect, aortic stenosis, etc.), biliary anomalies (gallbladder agenesis, choledochal cyst), visceral anomalies (splenic anomalies, intestinal malrotation), and skeletal anomalies have been reported. There are reports that the rate of associated congenital portosystemic shunt is high in Down syndrome (trisomy 21), suggesting an association with chromosomal abnormalities. In most cases, it occurs sporadically without a clear genetic cause.

3. Genetics

The genetic basis of anomalous portal venous connection (Q26.5) has not yet been sufficiently elucidated. Most cases occur sporadically and do not follow a Mendelian inheritance pattern due to a single-gene abnormality. However, some case reports and studies have suggested the possible involvement of genetic factors.

Genes involved in vascular development and hepatic vascular formation may have a potential association with portal anomalies. The NOTCH signaling pathway plays a key role in vascular development and arterial–venous differentiation, and variants in NOTCH1, NOTCH2, JAG1, and others are associated with various vascular malformations. In particular, JAG1 variants cause Alagille syndrome, in which hepatic vascular anomalies (pulmonary artery dysplasia, hepatic artery variants) accompany intrahepatic bile duct paucity. Portal anomalies have also been reported in some patients with Alagille syndrome.

The association between congenital portosystemic shunt and Down syndrome (trisomy 21) has been reported in several case series, and genes located on chromosome 21 are presumed to affect hepatic vascular development. However, the mechanism by which portal anomalies occur in Down syndrome has not yet been clearly established. Co-occurrence of congenital heart disease and portal anomalies has also been reported, suggesting a common developmental vulnerability.

Reports of familial portosystemic shunt are very rare, indicating that most cases are polygenic or sporadic rather than simple Mendelian inheritance. In studies using next-generation sequencing (NGS), variants in genes related to Hereditary Hemorrhagic Telangiectasia (HHT), such as ENG (endoglin) and ACVRL1 (ALK1), have been reported to be associated with portal anomalies accompanied by pulmonary arterial hypertension. Routine genetic testing is not currently recommended in clinical practice for patients with Q26.5, but genetic counseling is appropriate when there are chromosomal abnormalities such as Down syndrome, complex malformations, or a family history.

4. General epidemiology

Congenital anomalous portal venous connection (Q26.5) is a very rare congenital vascular malformation, and the prevalence of its best-known form, congenital portosystemic shunt (Abernethy malformation), is estimated at about 1/30,000–1/50,000. However, this figure is based on clinically diagnosed cases, and asymptomatic patients with mild shunts are presumed to be more numerous. In the case of patent ductus venosus, physiological closure may be delayed in the neonatal period, so the boundary between the early period and persistent patency is not clear.

Regarding sex distribution, several case series have consistently reported that congenital portosystemic shunt occurs more often in females, at about 2:1. Type 2 (partially preserved intrahepatic portal vein) is reported to be more common than type 1 (absent intrahepatic portal vein) and tends to have a better prognosis. Type 1 Abernethy malformation is more common in females and has a higher frequency of associated malformations (congenital heart disease, biliary anomalies, splenic anomalies).

Geographically, it occurs in all ethnic groups, but relatively many cases are reported in Asia (especially Japan). It is not clear whether this reflects an actual difference in prevalence or reporting bias. Because of the association with Down syndrome, it is clinically important that the incidence of congenital portosystemic shunt in cohorts of patients with Down syndrome is higher than in the general population.

Epidemiological data on the timing and frequency of complications are also important. In type 2 shunts, hyperammonemia and developmental delay are common in childhood, and when undiagnosed until adulthood, cases may present with liver nodules (focal nodular hyperplasia, hepatocellular adenoma, rarely hepatocellular carcinoma), pulmonary arterial hypertension, or hepatopulmonary syndrome. Liver nodule formation is reported in about 60–70% of adult patients with portosystemic shunts, including some with a risk of malignant transformation, so regular follow-up is necessary. Nephrolithiasis (uric acid kidney stones or ammonium magnesium phosphate stones due to hyperammonemia) is also a common complication.

5. Pathophysiology

The core pathophysiology of anomalous portal venous connection consists of various metabolic and organ abnormalities that occur because blood absorbed from the intestine, spleen, and pancreas cannot enter the liver and is diverted directly into the systemic circulation.

Impaired liver development: normally, portal blood flow supplies nutrients and growth factors essential for liver development and maintenance of liver size. In type 1 Abernethy malformation, in which portal flow is absent or markedly reduced, the liver is markedly atrophic or poorly developed, and the hepatic artery becomes compensatorily hypertrophied. Hepatocyte function is also reduced, and bile production, protein synthesis, and detoxification functions may decrease. When growth factors in portal blood that the liver should normally process (insulin, glucagon, hepatocyte growth factor, etc.) bypass the liver and enter the systemic circulation, they also affect organs other than the liver.

Hyperammonemia and hepatic encephalopathy: ammonia produced in the intestine is normally converted to urea in the liver through the urea cycle. When portal blood flow bypasses the liver, ammonia enters the systemic circulation and blood ammonia concentration rises (hyperammonemia), and ammonia delivered to the brain causes neurotoxicity, resulting in hepatic encephalopathy. In children, it may appear as developmental delay, learning disabilities, and behavioral abnormalities, and in adults it may progress to clouding of consciousness, disorientation, and hepatic coma.

Pulmonary complications: when vasoactive substances in portal blood (vascular endothelial growth factor, substance P, etc.) enter the pulmonary circulation without hepatic detoxification, they affect the pulmonary vessels. When pulmonary vasodilation (hepatopulmonary syndrome) occurs, intrapulmonary vascular dilation impairs oxygenation in the pulmonary capillaries, resulting in hypoxemia, cyanosis, and clubbing. Conversely, when pulmonary vasoconstriction and proliferation predominate, portopulmonary hypertension develops, which can gradually progress to right heart failure. Pulmonary arterial hypertension is an important complication in untreated adult patients with shunts.

Liver nodule formation: persistent diversion of portal blood flow alters the regenerative stimuli of the liver and can lead to the formation of focal nodular hyperplasia (FNH) or hepatocellular adenoma, and rarely progression to hepatocellular carcinoma. Nephrolithiasis occurs in the process of renal excretion of ammonia that has entered the systemic circulation, with formation of uric acid or struvite stones.

6. Symptoms

The clinical symptoms of anomalous portal venous connection vary extremely depending on the type of anomaly (complete vs. partial shunt, presence or absence of the portal vein), shunt volume, associated malformations, and patient age. They show a broad spectrum, from acute crises in the neonatal period to chronic progressive complications in adulthood.

Symptoms in the neonatal and infant period: with a severe shunt, neonatal hyperammonemia occurs early after birth, and feeding difficulty, lethargy, altered consciousness, seizures, and hypothermia may appear. Prolonged jaundice due to reduced bile secretion and cholestasis may accompany this. If there are associated cardiac malformations, cyanosis and dyspnea are added.

Symptoms in childhood: developmental delay, learning disabilities, and behavioral abnormalities are common symptoms, arising from neurotoxicity due to chronic mild hyperammonemia. Recurrent altered consciousness, nausea, vomiting, and hyperventilation (respiratory compensation for hyperammonemia) may appear. It may be mistaken for clinical findings mimicking galactosemia or urea cycle disorders. Kidney stones are sometimes found at a young age.

Symptoms in adulthood: when undiagnosed until adulthood, the main symptoms are episodes of hepatic encephalopathy (clouding of consciousness, disorientation, behavioral changes), reduced exercise capacity and dyspnea due to pulmonary arterial hypertension, and cyanosis due to hepatopulmonary syndrome. Liver nodules (FNH, adenoma, rarely hepatocellular carcinoma) are sometimes found on imaging. Patients may also complain of recurrent kidney stones, chronic fatigue, and cognitive decline.

Symptoms of complications: as pulmonary arterial hypertension progresses, dyspnea at rest, presyncope, lower-extremity edema, and symptoms of right heart failure appear. In hepatopulmonary syndrome, orthodeoxia, in which hypoxemia worsens on sitting or standing, is characteristic. When hepatocellular carcinoma develops, weight loss, right upper quadrant pain, and elevated alpha-fetoprotein appear.

7. Signs

Physical signs vary depending on the type of anomaly and whether complications have developed.

Abdominal findings: in type 1 Abernethy malformation, the liver may be markedly small or nonpalpable; conversely, hepatomegaly may appear due to liver nodules. Splenomegaly appears when there is accompanying portal hypertension (rare). Ascites is not uncommonly associated with type 1. Liver nodules are sometimes palpable on palpation of the right upper quadrant.

Neurological findings: in hepatic encephalopathy, impaired orientation, memory loss, hand tremor (flapping tremor, asterixis), constructional apraxia, and clouding of consciousness appear. In children, developmental delay, delayed language development, and attention deficit may be observed.

Pulmonary and cardiovascular findings: in hepatopulmonary syndrome, cyanosis, clubbing, decreased breath sounds, and orthodeoxia (lower SpO2 when standing than when lying down) are characteristic. In pulmonary arterial hypertension, an accentuated second heart sound, a tricuspid regurgitation murmur, right ventricular hypertrophy, and jugular venous distension are observed.

Skin findings: jaundice (in the neonatal period or with reduced liver function), spider angioma, and palmar erythema may be present.

Laboratory findings: elevated serum ammonia, elevated bile acids, reduced galactose tolerance, decreased albumin, prolonged prothrombin time, and an abnormal amino acid profile (elevated citrulline and argininosuccinic acid) may appear. Alpha-fetoprotein (AFP) rises when liver nodules or hepatocellular carcinoma develop.

8. Screening

Universal population screening for anomalous portal venous connection is not performed. However, active testing is needed in the following clinical situations.

Neonatal screening: when hyperammonemia of unknown cause occurs in the neonatal intensive care unit, congenital portosystemic shunt must be differentiated in addition to urea cycle disorders. Abdominal ultrasound (including Doppler) is performed along with neonatal ammonia testing (serum ammonia > 100-150 μmol/L or higher). Because newborns with Down syndrome have a high likelihood of an associated portosystemic shunt, portal blood flow is checked by abdominal ultrasound.

Childhood: abdominal Doppler ultrasound is performed to differentiate portosystemic shunt in children found to have unexplained developmental delay, behavioral abnormalities, recurrent hyperammonemia, kidney stones, hepatomegaly, or liver nodules. Serum ammonia, bile acid, and amino acid tests are also performed.

Adulthood: congenital portosystemic shunt must be differentiated in adults with unexplained hepatic encephalopathy, pulmonary arterial hypertension, hepatopulmonary syndrome, liver nodules (especially suspected FNH or adenoma), or recurrent kidney stones. Abdominal Doppler ultrasound is performed as the first-line test, and CT or MR angiography if necessary.

9. Diagnosis

The diagnosis of anomalous portal venous connection is made by confirming the vascular anatomy and assessing its functional impact.

Abdominal Doppler ultrasound: as the first-line noninvasive test, it evaluates the presence and diameter of the portal vein, the direction and velocity of blood flow, abnormal vascular connections, liver parenchymal structure, and liver nodules. Using Doppler, patency of the ductus venosus and the direction and velocity of flow in the shunt vessel can be measured directly.

CT/MR angiography: essential for three-dimensional visualization of the exact anatomical course, diameter, and connection site of the shunt vessel and the overall morphology of the portal venous system. CT has high resolution and is fast, while MRI can be used repeatedly without radiation exposure. MRI (dynamic contrast enhancement, liver-specific contrast agents) is also used to characterize liver nodules.

Nuclear medicine studies: liver scintigraphy evaluates liver function and the distribution of portal blood flow. Per-rectal portal scintigraphy is used to quantify the shunt fraction. Lung perfusion scanning (Tc-99m MAA) is used to quantify the right-to-left shunt in hepatopulmonary syndrome.

Laboratory tests: include serum ammonia, bile acids, amino acid profile, liver function tests (ALT, AST, bilirubin, albumin, prothrombin time), AFP, and blood gas analysis (assessment of hypoxemia). The serum galactose tolerance test is used as a sensitive indicator of liver function.

Liver biopsy: performed when characterization of liver nodules is needed. It is used to differentiate hepatocellular adenoma from hepatocellular carcinoma and to assess the degree of fibrosis.

Cardiovascular evaluation: when pulmonary arterial hypertension is suspected, echocardiography (estimation of pulmonary artery systolic pressure from tricuspid regurgitation velocity) and cardiac catheterization (measurement of pulmonary vascular resistance) are performed.

10. Treatment

Treatment of anomalous portal venous connection is individualized according to the type and anatomy of the shunt, the presence and severity of complications, and the patient's age.

Percutaneous vascular intervention (shunt closure): in type 2 shunts (partially preserved intrahepatic portal vein) and some small type 1 shunts, the shunt is closed by percutaneous embolization with coils or a vascular plug (Amplatzer occluder, etc.). Before the procedure, a balloon occlusion test is performed to check whether portal hypertension develops when the shunt is closed. After successful shunt closure, hyperammonemia may improve and liver development may be promoted.

Surgical treatment: when percutaneous access is anatomically difficult or when shunt closure and correction of associated malformations must be performed simultaneously, surgical ligation or shunt ligation with portal vein reconstruction is performed. In children, staged shunt closure (gradually reducing shunt volume while inducing liver development) is sometimes adopted.

Liver transplantation: in type 1 Abernethy malformation (liver agenesis or severe hepatic failure), when liver function does not recover even after shunt closure, or when there are malignant liver nodules, liver transplantation is the only curative treatment. After liver transplantation, portal blood flow normalizes, and hyperammonemia, hepatic encephalopathy, and hepatopulmonary syndrome may improve.

Medical management: to control hyperammonemia, a low-protein diet (protein restriction), lactulose (reduces intestinal ammonia production), rifaximin (suppresses intestinal bacteria), and zinc supplementation (a urea cycle cofactor) are used. For pulmonary arterial hypertension, pulmonary vasodilators (prostacyclin derivatives, endothelin receptor antagonists, PDE-5 inhibitors) are used. In hepatopulmonary syndrome, supplemental oxygen therapy helps relieve symptoms, but curative treatment is shunt closure or liver transplantation.

11. Prognosis

The prognosis of anomalous portal venous connection differs greatly according to the type of anomaly, shunt volume, timing of complications, and timing of treatment.

Type 2 shunts: when shunt closure is performed at the appropriate time, hyperammonemia improves and liver development is promoted, and the long-term prognosis is good. When diagnosed and treated early in childhood, normalization of development is possible, and pulmonary arterial hypertension and hepatopulmonary syndrome may also improve. After shunt closure, most liver nodules regress, but some persist and require long-term follow-up.

Type 1 Abernethy malformation: the prognosis is worse when there is no intrahepatic portal vein and liver development is poor. Shunt closure alone may not sufficiently restore liver function, and liver transplantation is often needed. With successful liver transplantation, the long-term prognosis is similar to that of liver transplant patients with other causes.

Untreated adult patients: when undiagnosed until adulthood, the risk of progression to serious complications such as pulmonary arterial hypertension, hepatopulmonary syndrome, and hepatocellular carcinoma is high. The prognosis is very poor when hepatocellular carcinoma develops. Therefore, when a shunt is found in an adult, the indications for treatment are carefully evaluated based on complications, and shunt closure or liver transplantation is performed when appropriate.

Long-term follow-up: even after treatment, regular serum ammonia, liver function tests, AFP, surveillance of liver nodules by abdominal imaging (ultrasound or MRI), and follow-up of pulmonary artery pressure are needed. In children, neurodevelopmental assessment is also performed regularly.

12. Prevention

Primary prevention of anomalous portal venous connection is difficult because most cases occur sporadically. General strategies to minimize the risk of fetal malformations during pregnancy are recommended, but a specific effect for this disease has not been established.

Early detection (secondary prevention): when evaluating neonatal hyperammonemia, portosystemic shunt is included in the differential diagnosis and abdominal Doppler ultrasound is performed. Preemptive abdominal ultrasound is recommended in newborns with Down syndrome. In children with unexplained developmental delay, recurrent hyperammonemia, or kidney stones, an active search for the cause contributes to early diagnosis.

Prevention of complications (tertiary prevention): after diagnosis, the type and functional impact of the shunt are evaluated to determine the indication for shunt closure. When hyperammonemia is present, shunt closure is planned while controlling it with a low-protein diet, lactulose, and rifaximin. Malignant transformation is detected early by regular imaging follow-up of liver nodules. Periodic echocardiography and blood gas analysis are performed for early detection of pulmonary arterial hypertension and hepatopulmonary syndrome.

13. References

  1. Morgan G, Superina R. Congenital absence of the portal vein: two cases and a proposed classification system for portasystemic vascular anomalies. J Pediatr Surg. 1994;29(9):1239-1241. PMID: 7807340.
  2. Baiges A, Turon F, Simón-Talero M, et al. Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): an International Observational Study. Hepatology. 2020;71(2):658-669. PMID: 31077596.
  3. Papamichail M, Pizanias M, Heaton N. Congenital portosystemic venous shunt. Eur J Pediatr. 2018;177(3):285-294. PMID: 29392434.
  4. Alonso-Gamarra E, Parrón M, Pérez A, et al. Clinical and radiologic manifestations of congenital extrahepatic portosystemic shunts: a comprehensive review. Radiographics. 2011;31(3):707-722. PMID: 21571654.
  5. Kobayashi N, Niwa T, Kirikoshi H, et al. Clinical classification of congenital extrahepatic portosystemic shunts. Hepatol Res. 2010;40(6):585-593. PMID: 20413967.
  6. Abernethy J. Account of two instances of uncommon formation in the viscera of the human body. Philos Trans R Soc Lond. 1793;83:59-66.
  7. Sokollik C, Bandsma RH, Gana JC, et al. Congenital portosystemic shunt: characterization of a multisystem disease. J Pediatr Gastroenterol Nutr. 2013;56(6):675-681. PMID: 23426453.
  8. Stringer MD. The clinical anatomy of congenital portosystemic venous shunts. Clin Anat. 2008;21(2):147-157. PMID: 18058906.
  9. Ohnishi Y, Ueda M, Kasahara M, et al. Successful liver transplantation for congenital absence of the portal vein complicated by intrapulmonary shunt and brain abscess. J Pediatr Surg. 2005;40(5):e1-e3. PMID: 15937820.
  10. Sanada Y, Mizuta K, Kawano Y, et al. Liver transplantation for congenital absence of the portal vein. Transplant Proc. 2012;44(2):476-479. PMID: 22410047.